Retrospective analysis of patients with disruptive mood dysregulation disorder and psychopharmacologic treatment preferences

Objective: DMDD is a new diagnosis listed in the DSM-5. Here, we aimed to present a retrospective analysis of cases with probable DMDD and their psychopharmacological treatment characteristics. Methods: 200 patients complaining of irritability and temper tantrums were evaluated retrospectively. To differentiate those with probable DMDD; Young Mania Rating Scale, Children's Depression Inventory, Screen for Anxiety and Related Disorders, Atilla Turgay Scale for DSM-IV-TR Disruptive Behavior Disorders scores were used. Results: 99 patients were found to fulfill criteria for DMDD. 85 patients (88 %) were prescribed drugs. Most common drugs were risperidone, methylphenidate, atomoxetine, OROS methylphenidate, sertraline and fluoxetine in descending order. Females are more frequently prescribed SSRIs while males are prescribed other drugs. Conclusion: As a new diagnosis, the treatment guidelines for DMDD are still unclear. The preliminary results of this study suggest that clinicians tend to prescribe stimulants/atomoxetine, atypical antipsychotics, and SSRIs for this group of patients.